Rachel W. Humphrey
63 works · 11,856 citations · h-index 27
Top works
- Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria
- Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
- Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study
- Four-year survival rates for patients with metastatic melanoma who received ipilimumab in phase II clinical trials
- Improved Endpoints for Cancer Immunotherapy Trials
- Efficacy and safety of ipilimumab induction and maintenance dosing in patients with advanced melanoma who progressed on one or more prior therapies
- Development of Ipilimumab: Contribution to a New Paradigm for Cancer Immunotherapy
- Novel efficacy criteria for antitumor activity to immunotherapy using the example of ipilimumab, an anti-CTLA-4 monoclonal antibody
- Antitumor response and new lesions in advanced melanoma patients on ipilimumab treatment
- Comparison of Gemcitabine Versus the Matrix Metalloproteinase Inhibitor BAY 12-9566 in Patients With Advanced or Metastatic Adenocarcinoma of the Pancreas: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group
- Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma
- Ipilimumab safety profile: Summary of findings from completed trials in advanced melanoma.
- CCR 20th Anniversary Commentary: Immune-Related Response Criteria—Capturing Clinical Activity in Immuno-Oncology
- Exposure–Response Relationships of the Efficacy and Safety of Ipilimumab in Patients with Advanced Melanoma
- Defining tumor resistance to PD-1 pathway blockade: recommendations from the first meeting of the SITC Immunotherapy Resistance Taskforce
- Phase I and Pharmacologic Study of the Specific Matrix Metalloproteinase Inhibitor BAY 12-9566 on a Protracted Oral Daily Dosing Schedule in Patients With Solid Malignancies
- Relative Potency of Protease Inhibitors in Monocytes/Macrophages Acutely and Chronically Infected with Human Immunodeficiency Virus
- Opportunities and Challenges in the Development of Experimental Drug Combinations for Cancer
- Detection of Serum Antibodies to a Kaposi's Sarcoma‐Associated Herpesvirus‐Specific Peptide
- Phase I study of the matrix metalloproteinase inhibitor, BAY 12-9566